The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Search
Advanced search
OR
Browse
Search
Volume 133, Issue 8
Displaying 1-8 of 8 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Guidelines
Seminar for Medical Education
Erratum
Original Articles
  • Long Term Follow-Up of Five Case -Series of Recalcitrant Pemphigus Vulgaris Treated with Rituximab
    Miwa Kanaoka, Setsuko Matsukura, Kazuko Nakamura, Yuko Ikezawa, Takesh ...
    2023 Volume 133 Issue 8 Pages 1857-1866
    Published: July 20, 2023
    Released on J-STAGE: July 20, 2023
    DOIhttps://doi.org/10.14924/dermatol.133.1857
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    Rituximab is an anti-CD20 monoclonal antibody that is widely used for recalcitrant pemphigus. It indnces remission by rapidly depleting the B cell population.

    We present five cases of pemphigus vulgaris treated with Rituximab in our hospital between 2010 and 2018. All of them have relapsed and been treated with a second cycle of rituximab. The average time to relapse was 28 months. In every case, we monitored clinical responses and decreases in autoantibody titers, which enabled us to taper corticosteroid and immunosuppressants. Average time of follow-up after first rituximab treatment was 81 months. There were no serious adverse reactions. We concluded that rituximab is efficacious for severe pemphigus resistant to combination therapies, including high-dose corticosteroid therapy, immunosuppressants and IVIG, and/or plasmapheresis.

    View full abstract
    Download PDF (774K)
Abstracts
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top